Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Asthmapolis Looks To Harness Data To Improve Asthma Care

This article was originally published in The Gray Sheet

  • News

Executive Summary

Wisconsin start-up aims to commercialize a system that links a standard asthma inhaler to a sensor and smartphone app by partnering with payers.

You may also be interested in...



For Asthmapolis, The Name Changes And The Focus Too

Digital health startup Asthmapolis has changed its name to Propeller Health, reflecting its broader focus to include chronic obstructive pulmonary disease.

Digital Health Briefs: Fall Risk Sensors, Asthmapolis Deal, Tooth Sensors

Meta-analysis on the use of sensors in care settings to monitor fall risk shows mixed results. Asthmapolis inks new deal with hospital system. More digital health briefs.

Digital Health In Brief

House Energy & Commerce Committee to hold hearings on health IT. More digital health news.

Table

View full table

Related Content

Medtech Insight
Medtech Insight

Topics

Tags:
Medical Device
Latest Headlines

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation

Second EU MDR Notified Body Designated In France

See All
UsernamePublicRestriction

Register

MT031573

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By